A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment (pages 370–378)Z. M. Younossi, F. H. Nader, C. Bai, R. Sjogren, J. P. Ong, R. Collantes, M. Sjogren, D. Farmer, L. Ramsey, K. Terra, H. Gujral, C. Gurung, M. Srishord and Y. Fang
Article first published online: 10 JAN 2008 | DOI: 10.1111/j.1365-2893.2007.00956.x